An open-label, randomized, phase 2 study of efficacy and tolerability of ABT-869 in advanced or metastatic non-small cell lung cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Linifanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors AbbVie
- 03 Aug 2012 Additional lead trial investigator (Ricker J) added as reported by ClinicalTrials.gov.
- 29 Dec 2011 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 19 Jul 2011 Planned End Date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History